BostonGene Announces Twelve Abstracts Selected for Presentation at the 66th American Society of Hematology Annual Meeting & Exposition

On December 6, 2024 BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, reported the selection of 10 abstracts for poster presentations and two abstracts for online publication at the 66th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, which will be held December 7-10, 2024, in San Diego, California. BostonGene will exhibit in booth #1955 (Press release, BostonGene, DEC 6, 2024, View Source [SID1234648860]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to present our research findings at ASH (Free ASH Whitepaper) that underscores the transformative potential of integrating molecular and immune profiling with advanced analytics. This approach is pivotal in advancing precision medicine and improving outcomes for individuals battling cancer," said Nathan Fowler, MD, Chief Medical Officer at BostonGene.

Details of the presentations are below:

Abstract: 1593
Title: Machine Learning-Based Approach to Improve Classification and Diagnostics of Peripheral T-Cell Lymphomas
Date & time: Saturday, December 7 | 5:30 PM -7:30 PM
Presenter: Anastasia Sobol, MS, BostonGene

BostonGene developed a machine learning-based classifier to aid in the diagnoses of peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) cases. Using this transcriptomic classifier to examine over 400 cases, approximately 50% of PTCL-NOS cases were reclassified into specific subtypes based on the gene expression pattern of each sample. These findings may enhance the understanding of PTCL pathogenesis and lead to improved diagnostic methods.

Research conducted in collaboration with Weill Cornell Medicine

Abstract: 3610
Title: Novel Plasma Cell-Free RNA-Based Liquid Biopsy Approach for CLL
Date & time: Sunday, December 8 | 6:00 PM – 8:00 PM
Presenter: Andrey Shubin, PhD, BostonGene

To address gaps in disease monitoring for chronic lymphocytic leukemia (CLL) patients, BostonGene developed a novel liquid biopsy approach based on plasma cell-free RNA (cfRNA) sequencing. From a simple blood draw, the cfDNA assay revealed malignant B-cell fractions, B-cell receptor repertoires and clinically significant mutations from cfRNA transcriptomes, as well as associations between treatment and immune- or tissue-specific processes. This liquid biopsy platform may support longitudinal monitoring CLL dynamics and minimal residual disease with further validation.

Research conducted in collaboration with Massachusetts General Hospital and Harvard Medical School

Abstract: 2981
Title: Gene Expression-Based Classifier Reclassifies Burkitt Lymphoma, HGBL NOS, DLBCL NOS, and Double/Triple Hit Lymphomas into Subtypes with More Uniform Mutational and Microenvironment Landscapes and Treatment Response
Date & time: Sunday, December 8 | 6:00 PM – 8:00 PM
Presenter: Juan Pablo Alderuccio, MD, Sylvester Comprehensive Cancer Center at the University of Miami

A machine learning-driven, expression-based classifier was applied to high-grade B-cell lymphomas, identifying subgroups based on unique genomic and transcriptomic features. Validated using large datasets, this classifier could accurately and repeatedly divide aggressive lymphoma cases into diffuse large B-cell and Burkitt lymphoma-like groups based on gene expression. These findings illustrate the clinical applications of a gene expression-based classifier in identifying subsets of patients with aggressive lymphomas.

Research conducted in collaboration with the Sylvester Comprehensive Cancer Center at the University of Miami

Abstract: 3038
Title: Acalabrutinib with Rituximab is Highly Effective as a First Line Treatment for Older Patients with Mantle Cell Lymphoma
Date & time: Sunday, December 8 | 6:00 PM – 8:00 PM
Presenter: Preetesh Jain, MD, MBBS, PhD, DM, The University of Texas MD Anderson Cancer Center

A phase II clinical trial for mantle cell lymphoma patients receiving acalabrutinib and rituximab demonstrated a 94% overall response rate, with 90% of patients achieving complete remission. Correlative analyses with next-generation sequencing and immunoprofiling techniques revealed key features of the immune system’s dynamics and adaptive response following treatment with the combination.

Research conducted in collaboration with the MD Anderson Cancer Center

Abstract: 2982
Title: Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma
Date & time: Sunday, December 8 | 6:00 PM – 8:00 PM
Presenter: Tony Zhuang, MD, MD Anderson Cancer Center

Transcriptomic analysis of pretreatment biopsies from advanced follicular lymphoma (FL) patients revealed that B-cell-associated gene signatures were linked with survival in FL patients receiving chemoimmunotherapy, while T-cell signatures correlated with improved outcomes in patients treated with lenalidomide and rituximab. These findings support the clinical application of transcriptomic profiling for FL patients.

Research conducted in collaboration with the MD Anderson Cancer Center

Abstract: 2958
Title: Circulating Tumor DNA Predicts Outcomes in Follicular Lymphoma: Analysis from a Prospective Study
Date & time: Sunday, December 8 | 6:00 PM – 8:00 PM
Presenter: Rahul Lakhotia, MBBS, National Institutes of Health

An ongoing prospective clinical trial examined the utility of serial circulating tumor DNA (ctDNA) for monitoring disease progression in follicular lymphoma patients. Detectable in over 90% of patients, baseline ctDNA levels correlated with FLIPI prognostic scores, total metabolic tumor volume and spontaneous regression. Serial ctDNA analysis accurately reflected tumor dynamics, demonstrating its value as a minimally invasive tool for tracking disease progression.

Research conducted in collaboration with the National Cancer Institute, University of South Florida, National Institutes of Health, Medical College of Georgia, University of Virginia, Adaptive Biotechnologies

Abstract: 4341
Title: Comprehensive Analysis of Malignant B-Cell Receptors Provides Insights into B-Cell Lymphoma Pathogenesis
Date & time: Monday, December 9 | 6:00 PM – 8:00 PM
Presenter: Evgeniia Alekseeva, PhD, BostonGene

Aimed at characterizing B-cell receptor (BCR) repertoires, BostonGene leveraged a blood-based approach to discover biomarkers capable of distinguishing B-cell lymphoma subtypes. Several features, including BCR isotype, IGVH somatic hypermutation rate and chain structure, were associated with specific subtypes, highlighting the potential for diagnostic biomarkers within BCR repertoires.

Abstract: 4377
Title: Radiation Therapy and Monocyte Activation in Large B-cell Lymphoma Patients Treated with CAR T-Cell Therapy
Date & time: Monday, December 9 | 6:00 PM – 8:00 PM
Presenter: Penny Fang, MD Anderson Cancer Center

A study evaluating CART-treated large B-cell lymphoma (LBCL) patients revealed radiation therapy reshapes the immune landscape, particularly by increasing monocyte levels, proliferation and cytotoxicity. This shift suggested radiation therapy is a viable bridging therapy for CART LBCL patients, promoting a suppressive immunotype linked with decreased toxicity and increased treatment response.

Research conducted in collaboration with the MD Anderson Cancer Center

Abstract: 4348
Title: Genomic and Spatial Proteomic Characterization of the Microenvironment of Diffuse Large B-Cell Lymphoma in African American Patients
Date & time: Monday, December 9 | 6:00 PM – 8:00 PM
Presenter: Michelle Lee, MD, PhD, Winship Cancer Institute of Emory University

A flagship multiomics study characterizing diffuse large B-cell lymphoma (DLBCL) in African American patients revealed the prevalence of immune-inflamed microenvironments, molecular alterations and distinct spatial cellular communities. These findings suggest tumor-specific factors may drive the disparity in survival outcomes and underscore the need for larger, more diverse clinical cohorts.

Research conducted in collaboration with the Winship Cancer Institute of Emory University, MD Anderson Cancer Center and Georgia Institute of Technology

Abstract: 4364
Title: Evaluating the clinical utility of comprehensive whole exome sequencing (WES) and RNA-seq for patients with lymphoma
Date & time: Monday, December 9 | 6:00 PM – 8:00 PM
Presenter: Dai Chihara, MD, PhD, MD Anderson Cancer Center

The BostonGene Tumor PortraitTM test, featuring integrated genomic and transcriptomic profiling, was used to generate clinically relevant findings, treatment recommendations and matched clinical trials for lymphoma patients. With a median turnaround time of just 8 days, the Tumor PortraitTM test’s robust findings and rapid turnaround time demonstrated the utility of integrated whole exome and transcriptome sequencing for lymphoma patients.

Research conducted in collaboration with the MD Anderson Cancer Center

Online only
Title: Tumor Genomics and Microenvironment Characterization of Diffuse Large B-Cell Lymphoma in Asian and Pacific Islander Patients

Integrated whole exome and transcriptome sequencing was performed on diffuse large B-cell lymphoma (DLBCL) tumors from the Hawaii Surveillance, Epidemiology, and End Results residual tissue repository, constituting an initial characterization of the DLBCL microenvironment in Asian and Pacific Islander patients, an under-represented population in prior studies. The findings suggest existing classification systems may not represent DLBCL heterogeneity in non-European populations, illustrating the need for studies with more diverse patient populations to reveal how ancestry, socioeconomic elements and environmental factors contribute to DLBCL pathobiology and outcomes.

Research conducted in collaboration with the Winship Cancer Institute of Emory University and MD Anderson Cancer Center

Title: Comprehensive Molecular Characterization of Monomorphic Post-Transplant Lymphoproliferative Disorder (PTLD)

Comparative analysis of Epstein-Barr virus (EBV)-positive and -negative post-transplant lymphoproliferative disorder (PTLD) patients with diffuse large B-cell lymphoma (DLBCL) uncovered distinct immune signatures and a higher prevalence of protumor elements among EBV-positive PTLD patients. When compared with immunocompetent-DLBCL, PTLD samples contained a higher fraction of plasma B-cells. While EBV-negative PTLDs largely resembled de novo DLBCLs, EBV-positive PTLDs were enriched with unique molecular features. These findings emphasize the role of EBV status in PTLD biology and associated clinical outcomes.

Research conducted in collaboration with the MD Anderson Cancer Center

In addition to the poster presentations, the abstracts have been published online in the November supplemental issue of "Blood."

Wugen to Present Clinical Data at the 2024 ASH Annual Meeting Ahead of Pivotal Trial Launch of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007

On December 5, 2024 Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, reported upcoming scientific presentations, including updates from the company’s Phase 1/2 study of WU-CART-007 (Press release, Wugen, DEC 5, 2024, View Source [SID1234648831]). Researchers will present Phase 1/2 updates and studies for its investigational cell therapies this week at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition, Dec. 7-10 in San Diego.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Results from Phase 1/2 showed continued anti-leukemic activity and clinically manageable safety in adults and adolescents. WU-CART-007 is an investigational, potential first-in-class, allogeneic, anti-CD7 CAR-T cell therapy under evaluation for treatment of patients with relapsed or refractory (R/R) T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma (T-ALL/LBL).

Based on findings to date with WU-CART-007, including this week’s data, Wugen will initiate the first pivotal Phase 2 study for an off-the-shelf CD7-targeted CAR-T cell therapy.

"Maturing evidence, including the Phase 1/2 study being presented, suggest WU-CART-007 has the potential to improve current standard of care for patients with these blood cancers. T-ALL/LBL are malignancies associated with high rates of relapse and mortality in patients, many of whom are young," said Armin Ghobadi, M.D, professor of medicine and clinical director of Center for Gene and Cellular Immunotherapy (CGCI) at the Washington University School of Medicine in St. Louis.

"At this year’s ASH (Free ASH Whitepaper) meeting, we will present clinical data from adult and adolescent patients that support our soon to open pivotal trial for patients with relapsed or refractory T-ALL/LBL," said Wugen Chief Medical Officer, Cherry Thomas, M.D. "We are looking forward to working with experienced investigators to provide meaningful clinical benefit to patients with limited treatment options."

The pivotal Phase 2 study is a single-arm trial evaluating the efficacy and safety of WU-CART-007 in patients with R/R T-ALL/LBL and T-ALL/LBL. The study will involve two groups: a R/R cohort and subsequently an exploratory minimal residual disease (MRD)-positive cohort. The trial will enroll pediatric and adult patients at oncology centers in the United States, Europe, Asia and Australia.

Wugen Presentations at ASH (Free ASH Whitepaper)

3450 WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results

Presenter: Armin Ghobadi, M.D., Washington University School of Medicine, St. Louis

Presentation type: Poster

Time/location: Sunday, Dec. 8, 6:00-8:00 p.m. PT; Halls G,H
Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II

3461 WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) – Subgroup Analysis of WU-CART-007 1001

Presenter: Shannon L. Maude, M.D., Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia, Philadelphia

Presentation type: Poster

Time/location: Sunday, Dec. 8, 6:00-8:00 p.m. PT; Halls G,H
Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II

Wugen researchers will also present the following abstracts for the company’s investigational memory natural killer cell therapy, WU-NK-101:

916 W-NK1 Choreographs Innate and Adaptive Immune Responses to Provide a Robust and Durable Anti-AML Response

Presenter: Tom Leedom, Wugen, Inc., St. Louis

Presentation type: Oral

Time/location: Monday, Dec. 9, 3:30 p.m. PT; Marriott Grand Ballroom 8-9, Marriott Marquis San Diego Marina

Session: 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Enhancing NK Cell Therapeutics Hematology Disease Topics & Pathways: Research, Translational Research 2:45-4:15 p.m. PT

4257 WUN101-01: First in Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Presenter: Amanda F. Cashen, M.D., Washington University School of Medicine, St. Louis

Presentation type: Poster

Time/location: Monday, Dec. 9, 6:00-8:00 p.m. PT; Halls G, H

Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III

Hematology Disease Topics & Pathways: Research, Clinical trials, Translational Research, Clinical Research

Investigator-initiated research

2066 Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients with CD7+ T-Cell Non-Hodgkin Lymphoma

Presenter: Michael H. Kramer, M.D., Ph.D., Washington University School of Medicine, Saint Louis

Presentation type: Poster

Time/location: Sat., Dec. 7, 5:30-7:30 p.m. PT; Halls G, H

Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I;

About WU-CART-007

WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat CD7+ hematological malignancies. Wugen is deploying CRISPR/Cas9 gene editing technology to delete CD7 and the T cell receptor alpha constant (TRAC), preventing CAR-T cell fratricide and mitigating the risk of graft-versus-host-disease (GvHD). WU-CART-007 is manufactured using healthy donor-derived T cells to eliminate the risk of malignant cell contamination historically observed in the autologous CAR-T setting. WU-CART-007 is currently being evaluated in a global Phase 1/2 clinical trial for the treatment of relapsed or refractory (R/R) T cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL). More information on the Phase 1/2 trial is available on clinicaltrials.gov, identifier NCT# 04984356 and on the Phase 2 pivotal trial on clinicaltrials.gov, identifier NCT06514794.

WU-CART-007 has received Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration and Priority Medicines (PRIME) Scheme designation in the European Union for the treatment of relapsed/refractory (R/R) T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL). RMAT and PRIME designations provide increased agency support to expedite the development and review of promising therapies for patients in need.

Foresight Diagnostics Announces Launch of SHORTEN-ctDNA Trial to Evaluate Personalized Treatment Duration in DLBCL Lymphoma Patients

On December 5, 2024 Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, reported the launch of SHORTEN-ctDNA, a clinical trial at Columbia University (Press release, Foresight Diagnostics, DEC 5, 2024, View Source [SID1234648847]). The study aims to evaluate the ability to utilize Foresight CLARITY MRD detection to enable real-time treatment optimization for patients with diffuse large B-cell lymphoma (DLBCL).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Currently the standard treatment for newly diagnosed DLBCL requires six cycles of combination rituximab and chemotherapy regardless of individual patient response. This one-size-fits-all approach leaves little room for personalization, potentially exposing patients to unnecessary treatment. The SHORTEN-ctDNA trial will investigate whether patients who achieve early clearance of circulating tumor DNA (ctDNA) can safely receive fewer cycles of chemotherapy while maintaining long-term survival outcomes.

"Although PET scans remain our standard tool for monitoring lymphoma treatment, their inconsistent results in identifying active disease limit our ability to make real-time treatment decisions," said David Kurtz, MD, PhD, Chief Medical Officer and Head of Research at Foresight Diagnostics. "Foresight CLARITY’s detection of residual disease could be the game-changer we need, potentially allowing us to confidently adjust therapy based on each patient’s actual response to treatment with a more dynamic and sensitive tool than imaging."

The study will enroll approximately 32 newly diagnosed DLBCL patients. After three cycles of R-CHOP or pola-R-CHP therapy, participants will undergo ctDNA testing. Those with detectable disease (MRD-positive) will continue with rituximab plus chemotherapy for their remaining cycles, while patients who achieve undetectable ctDNA levels (MRD-negative) will de-escalate to rituximab alone for their final two cycles.

"Recent evidence suggests many patients achieve very deep remissions earlier in their R-chemo treatment than previously thought," said Hua-Jay Cherng, MD, assistant professor of medicine at Columbia University Vagelos College of Physicians and Surgeons and Principal Investigator of the study. "By using next-generation, ultra-sensitive ctDNA technology, SHORTEN-ctDNA aims to identify these early responders and personalize their treatment strategy, potentially reducing treatment duration and associated toxicity and hopefully getting patients back to their normal lives sooner."

FORE Biotherapeutics to Participate in the Wells Fargo Virtual Private Biotech Symposium

On December 5, 2024 FORE Biotherapeutics reported that the Company will participate in the Wells Fargo Virtual Private Biotech Symposium on Thursday, December 12 (Press release, Fore Biotherapeutics, DEC 5, 2024, View Source [SID1234648824]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

William Hinshaw, Chief Executive Officer and Michael Byrnes, Chief Financial Officer, will host and participate in one-on-one meetings. Please contact Argot Partners to schedule one-on-one meetings with the management team.

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program

On December 5, 2024 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat cancers, reported it has entered into a Clinical Trial Services Agreement (the "Agreement") with the Israel-based biotechnology company PeriNess Ltd. ("PeriNess") to advance the Company’s development program for its systemic DNase I candidate in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors toward exploratory clinical studies (Press release, Xenetic Biosciences, DEC 5, 2024, View Source [SID1234648832]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to be working with PeriNess, and to have the opportunity to leverage their experience for the development of Xenetic’s intravenous DNase I candidate through preclinical and early-stage clinical programs. We are excited to take this step forward on the path to the clinic and look forward to investigating our systemic DNase I candidate, XBIO-015, as an adjunctive treatment," commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.

"We are thrilled to enter this strategic Clinical Trial Services Agreement with Xenetic and further advance the development of their systemic DNase I platform. We believe this collaboration is a great example of where we can put substantial synergies from our projects toward accelerating the clinical development of a highly promising DNase I program for patients in need of new therapies," commented Michal Ben Attar, Chief Executive Officer of PeriNess.

A large body of published preclinical data highlights the pivotal role of Neutrophil Extracellular Traps (NETs) in modulating cancer chemotherapy and immunotherapy efficacy and provides a strong rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients with pancreatic and colorectal cancers receiving chemotherapy and immunotherapy.

Under the terms of the Agreement, PeriNess will lead in the regulatory approval, operational execution and management of potential exploratory, investigator initiated studies of recombinant DNase as an adjunctive treatment in patients with pancreatic carcinoma and other locally advanced or metastatic solid tumors receiving chemotherapy and immunotherapy in Israeli medical centers.